Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2016-04-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
审计报告
Audit Report / Information Classification · 95% confidence The document is titled '审计报告' (Audit Report) and includes detailed sections such as the audit report itself, audited financial statements (balance sheet, income statement, cash flow statement, statement of changes in equity), and extensive financial statement notes. It references the audit opinion issued by a registered accounting firm (瑞华审字 [2016]12020009 号) for the fiscal year ending December 31, 2015. The content includes management responsibilities, auditor responsibilities, accounting policies, and detailed financial disclosures. The document length is substantial (15,000 characters) and contains the full audit report and financial statements, not just an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) because it is specifically the audit report and related financial statements, not the entire annual report with management discussion and other sections. Hence, the classification is AR with high confidence. FY 2015
2016-04-29 Chinese
2015年年度报告摘要
Annual Report Classification · 98% confidence The document is titled as the 2015 annual report summary of 中源协和细胞基因工程股份有限公司, containing detailed financial data, business overview, management discussion and analysis, profit and loss statements, cash flow data, and shareholder information. It includes audited financial figures, business segment performance, and strategic discussions typical of a full annual report. The length is substantial (15,000 characters), and it contains actual financial statements and substantive analysis rather than just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2015
2016-04-29 Chinese
第一期员工持股计划持有人会议第一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at a meeting of holders of an employee stock ownership plan. It details the meeting date, attendance, voting results, and decisions made regarding the establishment of a management committee, election of committee members, stock purchase methods, and authorization of committee responsibilities. There is no financial data, no mention of annual or quarterly reports, no audit information, no earnings release, and no regulatory certifications. The document is a formal announcement of meeting resolutions related to employee stock ownership plan governance and management. It fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories like Board/Management Information or Share Issue/Capital Change, since it concerns employee stock plan management rather than direct board changes or capital issuance. The document length is short and it is an announcement, not a full report or detailed financial disclosure.
2016-04-21 Chinese
关于增资深圳碳云智能科技有限公司的进展公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding an investment increase (增资) in another company, Shenzhen Carbon Cloud Intelligent Technology Co., Ltd. It details the amount invested, the resulting shareholding percentage, and the updated equity structure of the target company. There is no indication of financial statements, audit information, or regulatory certifications. The document is an update on capital investment activity, specifically about the company's financing or capital structure changes. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA or RNS.
2016-04-20 Chinese
关于转让湖州融源瑞康股权投资合伙企业（有限合伙）合伙份额的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the transfer of partnership shares in an investment partnership (湖州融源瑞康股权投资合伙企业) by the company 中源协和细胞基因工程股份有限公司. It includes transaction details, parties involved, financial figures, agreements, and the impact on the company. There is no indication that this is a financial report, audit, earnings release, or regulatory certification. The content focuses on a capital transaction involving the transfer of investment shares and related agreements, which fits the definition of a Capital/Financing Update (CAP). The document length is 4467 characters, which is sufficient for a full announcement rather than a brief notice or report publication announcement. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2016-04-11 Chinese
独立董事关于第八届董事会第四十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding specific board meeting matters, including a transaction and an equity transfer. It references compliance with governance guidelines and the board meeting number but does not contain financial statements or detailed financial results. It is not a full annual or interim report, nor an earnings release. It is not a regulatory filing or certification letter. The content aligns with Board/Management Information (MANG) as it relates to board meeting decisions and opinions from directors on company matters.
2016-04-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.